INFO SHEET

HUB Organoids in Preclinical Toxicology

About 30% of drugs fail human trials because of toxicity, despite promising preclinical safety tests The high attrition rate can be attributed to the poor predictive value of conventional preclinical models. 2D cell cultures, like Caco-2 cells, often fail to replicate the cellular complexity of human tissues, and animal models do not fully represent human-specific toxicities due to species differences.

HUB Organoids derived from patients accurately mirror the physiology and genetic makeup of the source tissue, offering a reliable platform for evaluating the toxicity of drugs. Our sophisticated culture methods facilitate the combination of immune cells and stromal elements in a co-culture system, accurately simulating the tissue’s microenvironment complexity.

By downloading this infosheet you will:

• Uncover the Advantages of HUB Organoids: Learn what makes HUB Organoids the perfect choice for preclinical exploratory toxicology studies.
  
  
• Explore Our Toxicology Portfolio: Discover our comprehensive toxicology offerings, including patient-derived organoid models, monolayers, and co-cultures.
  
  
• Unlock the Power of PDOs in Toxicology: See how patient-derived organoids (PDOs) can be applied throughout the exploratory toxicology process
  1. Early evaluations of on-target and off-target toxicities.
  2. Informed species selection for further toxicology studies.
  3. Late-stage investigations focusing on translating animal data to human organoid responses.
  
  
• Witness the Proof: Explore real-world data showcasing the effectiveness of human and animal-derived organoids in exploratory toxicology.